Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761909 | 0.90 | EGLN1 (0.47) | EGLN1BBOX1FTOEGLN3 | |
| SCHEMBL933166 | 0.87 | — | — | |
| SCHEMBL934000 | 0.86 | — | — | |
| SCHEMBL11933998 | 0.86 | PTPRC (0.43) | CYP2C19EGLN1EGLN3 | |
| SCHEMBL10009819 | 0.85 | — | — | |
| SCHEMBL934353 | 0.84 | EGLN1 (0.46) | EGLN1BBOX1EGLN3 | |
| SCHEMBL933443 | 0.82 | CYP2C19 (0.48) | CYP2C19 | |
| SCHEMBL934174 | 0.81 | — | — | |
| SCHEMBL27961481 | 0.81 | — | — | |
| SCHEMBL934015 | 0.80 | EGLN1 (0.47) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454249-B1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO LTD (CN) | 2018-09-19 | — | — | EP | claimed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | claimed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | claimed |
| EP-2454249-B1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO LTD (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| EP-2454249-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | Zhejiang Beta Pharma Inc. (CN) | 2012-05-23 | — | — | EP | disclosed |
| CN-102164905-A | Compounds, compositions, and uses thereof as hypoxia mimetics | BEIJING BETA PHARMA INC | 2011-08-24 | — | — | CN | disclosed |
| WO-2011006355-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSITIONS, AND USES THEREOF | BEIJING BETA PHARMA INC. (CN) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | HIF1AN, HIF1A, EGLN3 | CYP2C19 3820/4885EGLN1 5/4885BBOX1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.